CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Crescent Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Crescent Biopharma Inc
9708 Medical Center Drive
Phone: (240) 243-1201p:240 243-1201 ROCKVILLE, MD  20850  United States Ticker: CBIOCBIO
This company was Merged or Acquired on 6/16/2025.
This is a Subsidiary, click here for the Parent Company
Business Summary
Crescent Biopharma Inc., formerly GlycoMimetics, Inc., is a biotechnology company. The Company is engaged in advancing novel precision-engineered molecules to advance care for patients with solid tumors. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads for undisclosed targets. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Senior Vice President, Chief Commercial Officer BruceJohnson 57 2/23/2022 2/23/2022
Senior Vice President, Chief Business Officer ChinmayaRath 49 2/1/2023 2/1/2023

Business Names
Business Name
CBIO
Gemini Merger Sub Corp.
Gemini Merger Sub II, LLC
GLYC

General Information
Number of Employees: 4 (As of 1/31/2025)
Outstanding Shares: 645,321 (As of 6/16/2025)
Shareholders: 20
Stock Exchange: NASD
Federal Tax Id: 061686563
Fax Number: (240) 243-1018


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, July 3, 2025